Beyond binding: antibody effector functions in infectious diseases

LL Lu, TJ Suscovich, SM Fortune, G Alter - Nature Reviews Immunology, 2018 - nature.com
Antibodies play an essential role in host defence against pathogens by recognizing
microorganisms or infected cells. Although preventing pathogen entry is one potential …

Engaging innate immunity in HIV-1 cure strategies

NL Board, M Moskovljevic, F Wu, RF Siliciano… - Nature Reviews …, 2022 - nature.com
Combination antiretroviral therapy (ART) can block multiple stages of the HIV-1 life cycle to
prevent progression to AIDS in people living with HIV-1. However, owing to the persistence …

Latent HIV reservoirs exhibit inherent resistance to elimination by CD8+ T cells

SH Huang, Y Ren, AS Thomas, D Chan… - The Journal of …, 2018 - Am Soc Clin Investig
The presence of persistent, latent HIV reservoirs in CD4+ T cells obstructs current efforts to
cure infection. The so-called kick-and-kill paradigm proposes to purge these reservoirs by …

Elimination of HIV-1-infected cells by broadly neutralizing antibodies

T Bruel, F Guivel-Benhassine, S Amraoui… - Nature …, 2016 - nature.com
The Fc region of HIV-1 Env-specific broadly neutralizing antibodies (bNAbs) is required for
suppressing viraemia, through mechanisms which remain poorly understood. Here, we …

Strategies to eradicate HIV from infected patients: elimination of latent provirus reservoirs

I Sadowski, FB Hashemi - Cellular and Molecular Life Sciences, 2019 - Springer
Abstract 35 years since identification of HIV as the causative agent of AIDS, and 35 million
deaths associated with this disease, significant effort is now directed towards the …

[HTML][HTML] Immunological approaches to HIV cure

AR Ward, TM Mota, RB Jones - Seminars in immunology, 2021 - Elsevier
Combination antiretroviral therapy (ART) to treat human immunodeficiency virus (HIV)
infection has proven remarkably successful–for those who can access and afford it–yet HIV …

Multimeric immunotherapeutic complexes activating natural killer cells towards HIV-1 cure

R Schober, B Brandus, T Laeremans… - Journal of Translational …, 2023 - Springer
Background Combination antiretroviral therapy (cART) has dramatically extended the life
expectancy of people living with HIV-1 and improved their quality of life. There is …

[HTML][HTML] The potential of engineered antibodies for HIV-1 therapy and cure

M Grobben, RAL Stuart, MJ van Gils - Current opinion in virology, 2019 - Elsevier
Highlights•Therapy combining two or more antibodies show promising results in clinical
trials.•Fc domain engineering can improve antibody half-life and enhance effector …

Co-receptor binding site antibodies enable CD4-mimetics to expose conserved anti-cluster A ADCC epitopes on HIV-1 envelope glycoproteins

J Richard, B Pacheco, N Gohain, M Veillette, S Ding… - …, 2016 - thelancet.com
Human immunodeficiency virus type 1 (HIV-1) has evolved a sophisticated strategy to
conceal conserved epitopes of its envelope glycoproteins (Env) recognized by antibody …

Fighting HIV-1 persistence: At the crossroads of “shoc-K and B-Lock”

C Acchioni, E Palermo, S Sandini, M Acchioni, J Hiscott… - Pathogens, 2021 - mdpi.com
Despite the success of highly active antiretroviral therapy (HAART), integrated HIV-1 proviral
DNA cannot be eradicated from an infected individual. HAART is not able to eliminate …